Business Wire

ADTRAN

11.3.2024 14:02:25 CET | Business Wire | Press release

Share
Netnod bolsters Sweden’s national timing infrastructure with Adtran Oscilloquartz optical cesium clocks

Adtran today announced that Netnod is leveraging its optical pumping cesium atomic clock technology to bring precise, reliable and assured timing to Sweden’s critical national infrastructure. Protecting the country’s timing services is vital for the nation’s economy, encompassing finance, digital services and next-generation telecoms networks, such as 5G. By upgrading its timing network with the coreSync OSA 3300-HP, Netnod, the leading provider of internet exchange, DNS and time services in the Nordics, is enhancing the accuracy, stability and longevity of synchronization services across the region. The solution meets the need for precise timing, supporting the smooth operation and evolution of digital applications and services. It represents a significant advancement in timing that enhances Sweden’s position in digital innovation and cybersecurity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311684053/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Netnod is using Adtran’s synchronization technology for ultra-precise and reliable timing across Sweden’s national critical infrastructure. (Photo: Business Wire)

“At Netnod, we’re committed to providing the market’s most advanced and reliable timing solutions. Our new Time Direct and Remote services, built on the latest timing standards and security protocols, underscore our leadership in this domain. The deployment of Adtran’s coreSync OSA 3300-HP is key for providing reliable, continuous timing for Sweden’s critical infrastructure. It enhances our NTP/PTP services and strengthens Sweden’s digital backbone for essential sectors, including 5G. It also provides the country with the benefits of highly precise synchronization resilient against GNSS vulnerabilities and enables us to deliver more valuable SLAs for our customers,” said Karin Ahl, CEO of Netnod. “This upgrade is about securing the digital backbone of our nation against GNSS cyber threats, generating economic growth and reinforcing our commitment to maintaining Sweden as a leader in digital innovation and infrastructure resilience.”

Netnod is integrating Oscilloquartz super ePRC technology across six key timing centers nationwide, including the coreSync OSA 3300-HP, for unprecedented reliability and accuracy. The upgrade is particularly crucial for timing service assurance within a secure environment. Given the increasing vulnerabilities of GNSS, the optically pumped cesium technology offers a highly stable and accurate alternative timing source. The coreSync OSA 3300-HP sets new standards with its higher frequency stability and lifespan that is twice as long as traditional magnetic clocks. Its robust design is complemented by a user-friendly LCD touchscreen and Ethernet connectivity, facilitating both local and remote configuration and management. This blend of advanced features enhances time synchronization across Sweden and prepares the nation’s infrastructure for future challenges.

“Netnod is a major hub for ICT and multimedia, serving as the gateway to the Nordics’ global digital arena. Leveraging our coreSync OSA 3300, it’s fortifying Sweden’s critical national infrastructure, ensuring seamless operations and growth for internet service providers, content delivery networks and businesses in one of Europe’s most dynamic digital markets,” commented Stuart Broome, GM of EMEA sales at Adtran. “With our technology, Netnod can utilize multiple timing sources, enabling a zero-trust environment for clients in next-gen telecoms, finance, utilities, broadcast and beyond. This will help equip enterprises and institutions across the region with top-tier internet speed, resilience and connectivity and solidify Netnod’s position as the digital cornerstone of the Nordics.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

About Netnod

Netnod provides critical infrastructure support ranging from interconnection services and Internet Exchanges to time services, DNS services and root server operations. With a worldwide reputation for its services and the expertise of its staff, Netnod ensures a stable and secure Internet for the Nordics and beyond. Established in 1996 as a neutral and independent Internet infrastructure organisation, Netnod is fully owned by the non-profit foundation TU-stiftelsen (Stiftelsen för Telematikens utveckling). More information is available at: www.netnod.se.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240311684053/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye